Jim Cramer Believes “Novo Nordisk Is Going to Lose a Lot of Share on the Pill to Eli Lilly”

Novo Nordisk A/S (NYSE:NVO) was among the stocks Jim Cramer covered on Mad Money as he discussed the wave of IPOs being the market’s possible biggest threat. A caller asked if they should hold the stock or not, and in response, Cramer said:

Oh, Novo Nordisk, no, look, Eli Lilly’s struggling right here. I think, and Novo Nordisk is going to lose a lot of share on the pill to Eli Lilly. So I say no, we don’t want to be there.

Photo by Adam Nowakowski on Unsplash

Novo Nordisk A/S (NYSE:NVO) manufactures pharmaceuticals for chronic conditions, including diabetes, obesity, and rare blood or endocrine disorders. The company also produces some medical devices. On January 29, answering a caller’s question about the stock, Cramer said:

I kind of liked it when I spoke to them. I gotta tell you, I kind of warmed up… I was in San Francisco, and I said, you know what? I get that stock a little down more… But I love Eli Lilly and David Ricks, and what can I say? You know, as long as Eli Lilly and David Ricks are putting up those numbers and they get that pill form soon, I think that Novo is a hold, not a buy.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Disclosure: None. Follow Insider Monkey on Google News.